We studied the distribution of serum cholesterol, triglycerides, phospholipids, free fatty acid and serum lipoprotein fraction levels after more than 12 hours' fasting in 189 cases of benign prostatic hypertrophy and 29 cases of untreated prostatic cancer, who were not complicated with cardiovascular disturbances, and additionally in 17 cases of the benign prostatic hypertrophy complicated with cardiovascular disease and 28 cases of other non-advanced urogenital tumors (23 cases of bladder tumor, 3 cases of kidney cancer and 2 cases of testicular tumor). All the patients were over 50 years old. Lipoprotein fractions were measured by agarose-gel-electrophoresis. The results were as follows;1) The serum lipid values of the group of benign prostatic hypertrophy without cardiovascular disturbances did not show any significant differences from the values of 43 cases of the control group. In lipoprotein fractions, β-lipoprotein fraction values were found to be lower than those of the control group, but within the normal range.2) The fluctuations of serum lipids and lipoprotein fractions with age were observed in the group of benign prostatic hypertrophy without cardiovascular disturbances as well as those in 447 cases of Japanese healthy elder males.3) In the prostatic cancer group, the serum lipids levels were not particularly different from the other groups except for the group of benign prostatic hypertrophy complicated with cardiovascular disturbances, while in lipoprotein fractions, some significant increase of β+Pre-β/α lipoprotein fraction ratio was observed. Also, there was observed a high frequency of hyperlipoproteinemia, actually as high as in the group of benign prostatic hypertrophy complicated with cardiovascular disturbances.In view of the above results, differences of β+Pre-β/α lipoprotein fraction ratio between the group of benign prostatic hypertrophy without cardiovascular disturbances and the group of prostatic cancer was clearly observed. The fact that there were many cases who already had hyperlipoproteinemia in the prostatic cancer group was an interesting finding, when this is considered together with the fact that cardiovascular complications are caused by estrogen treatment to the patients with carcinoma of the prostate.